1
|
Das R, Strowig T, Verma R, Koduru S, Hafemann A, Hopf S, Kocoglu MH, Borsotti C, Zhang L, Branagan A, Eynon E, Manz MG, Flavell RA, Dhodapkar MV. Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. Nat Med 2016; 22:1351-1357. [PMID: 27723723 PMCID: PMC5101153 DOI: 10.1038/nm.4202] [Citation(s) in RCA: 112] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2016] [Accepted: 09/13/2016] [Indexed: 02/07/2023]
Abstract
Most human cancers including myeloma are preceded by a precursor state.
There is an unmet need for in vivo models to study the
interaction of human preneoplastic cells in the bone marrow microenvironment
with non-malignant cells. Here, we genetically humanized mice to permit the
growth of primary human pre-neoplastic and malignant plasma cells together with
non-malignant cells in vivo. Growth was
largely restricted to the bone marrow, mirroring the pattern in patients.
Xenografts captured the genomic complexity of parental tumors and revealed
additional somatic changes. Moreover, xenografts from patients with
preneoplastic gammopathy showed progressive growth, suggesting that the clinical
stability of these lesions may in part be due to growth controls extrinsic to
tumor cells. These data demonstrate a new approach to investigate the entire
spectrum of human plasma cell neoplasia and illustrate the utility of humanized
models for understanding the functional diversity of human tumors.
Collapse
Affiliation(s)
- Rituparna Das
- Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Till Strowig
- Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Rakesh Verma
- Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Srinivas Koduru
- Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Anja Hafemann
- Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Stephanie Hopf
- Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Mehmet H Kocoglu
- Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Chiara Borsotti
- Division of Hematology, University Hospital Zurich, Zurich, Switzerland
| | - Lin Zhang
- Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Andrew Branagan
- Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Elizabeth Eynon
- Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Markus G Manz
- Division of Hematology, University Hospital Zurich, Zurich, Switzerland
| | - Richard A Flavell
- Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.,Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Madhav V Dhodapkar
- Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.,Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.,Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, USA
| |
Collapse
|